Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Provided By GlobeNewswire
Last update: May 22, 2025
Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety.
Read more at globenewswire.com2.28
-0.12 (-5%)
Find more stocks in the Stock Screener
IMMX Latest News and Analysis
19 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.
